Leap Therapeutics cut to Neutral at Baird after mid-stage trial setback
Leap Therapeutics (NASDAQ:LPTX) fell ~12% on Wednesday as Baird downgraded the stock after the biotech said its lead candidate, sirexatamab, generated disappointing data in a mid-stage trial for ...
oncnursingnews4 小时
Trastuzumab Combo Shows Numerical Survival Benefit in Gastric/GEJ Cancer
The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with ...
labiotech6 小时
Pancreatic cancer: Oncolytics Biotech, Candel, and CytomX bring promising therapies to the ...
Discover new treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to ...
Leap Therapeutics stock rating cut by H.C. Wainwright to Neutral
H.C. Wainwright adjusted its stance on Leap Therapeutics (NASDAQ:LPTX), downgrading the biopharmaceutical company's stock ...
Rising Cases of Gastric Cancer Among Younger Adults: A Call for Awareness
Several risk factors contribute to the development of gastric cancer, ranging from bacterial infection from Helicobacter ...
Studies show an alarming disparity in stomach cancer rates in different races
A new report from the National Cancer Institute shows a major disparity in the rates of stomach cancer in people of different ...